Skip to main content
. 2022 Apr;13(2):780–786. doi: 10.21037/jgo-22-239

Table 3. Lenvatinib-related adverse events.

Adverse event All grades, n (%) Grade 3, n (%) Grade 4, n (%)
Hypertension 4 (33.3) 1 (8.3) 0
Fatigue 1 (8.3) 0 0
Myalgia 1 (8.3) 0 0
Hand-foot skin reaction 1 (8.3) 0 0
Rush 1 (8.3) 0 0
Decreased appetite 1 (8.3) 0 0
Decreased platelet 1 (8.3) 0 0
Diarrhea 1 (8.3) 0 0
Edema 1 (8.3) 0 0